HLS Therapeutics Inc (DE:74D)
FRANKFURT:74D
74D Stock Chart & Stats
€2.72
-€0.06(-2.36%)
At close: 4:00 PM EST
€2.72
-€0.06(-2.36%)
Day’s Range― - ―
52-Week Range€2.50 - €3.42
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€86.96M
Enterprise Value€133.66M
Total Cash (Recent Filing)€12.33M
Total Debt (Recent Filing)€43.96M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 06, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding31,273,682
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.80
Price to Sales (P/S)1.96
P/FCF Ratio7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.44Price Target Upside63.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€36.14M
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained operating cash flow and very strong free cash flow provide durable internal funding to support commercialization, acquisitions, and debt reduction. This cash conversion cushions the business versus accounting losses and enables strategic flexibility over the next several quarters.
Asset-light Commercialization ModelThe company's model of acquiring or licensing late-life-cycle branded drugs and using its commercial infrastructure reduces R&D risk and accelerates time-to-revenue. This repeatable BD-led approach supports predictable product cash flows if deal sourcing and commercialization capabilities remain intact.
Improved Margins (gross/EBITDA)Sharply improved gross margin and healthy EBITDA margins point to efficient product economics and pricing power on marketed products. These operating-margin improvements underpin sustained cash generation, even if accounting net income remains negative, improving long-term resilience.
Bears Say
Persistent Net Losses & Negative ROEMaterial negative net margin and negative return on equity indicate the business is not yet producing accounting profits; over time, continued losses can erode shareholder equity, restrict capital options, and hinder trust from lenders and partners unless profitability inflects.
Revenue VolatilityRevenue has been uneven, with a down year and a period of flat sales before modest recent growth. Reliance on product lifecycle timing and deal-driven revenue makes top-line consistency vulnerable, complicating forecasting and the ability to scale fixed commercial costs sustainably.
Debt Coverage RiskAlthough cash flow is strong, coverage of total debt is only about 0.65x, meaning deleveraging depends on maintaining or increasing cash generation. A prolonged cash slowdown or larger financing needs could pressure liquidity and raise refinancing risk amid ongoing accounting losses.
HLS Therapeutics Inc News
74D FAQ
What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was €2.50 and its highest was €3.42 in the past 12 months.
What is HLS Therapeutics Inc’s market cap?
HLS Therapeutics Inc’s market cap is €86.96M.
When is HLS Therapeutics Inc’s upcoming earnings report date?
HLS Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 59 days.
How were HLS Therapeutics Inc’s earnings last quarter?
HLS Therapeutics Inc released its earnings results on Mar 12, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of -€0.026 by -€0.009.
Is HLS Therapeutics Inc overvalued?
According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued.
Does HLS Therapeutics Inc pay dividends?
HLS Therapeutics Inc does not currently pay dividends.
What is HLS Therapeutics Inc’s EPS estimate?
HLS Therapeutics Inc’s EPS estimate is -0.07.
How many shares outstanding does HLS Therapeutics Inc have?
HLS Therapeutics Inc has 31,273,682 shares outstanding.
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
HLS Therapeutics Inc reported an EPS of -€0.035 in its last earnings report, missing expectations of -€0.026. Following the earnings report the stock price went up 1.5%.
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:74D
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
74D Stock 12 Month Forecast
Average Price Target
€4.44
▲(63.36% Upside)
Technical Analysis
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Aequus Pharmaceuticals
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
Options Prices
Currently, No data available
---